<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The factors regulating the growth of follicular dendritic cell (<z:chebi fb="17" ids="38848">FDC</z:chebi>) <z:hpo ids='HP_0100242'>sarcoma</z:hpo> are currently unknown </plain></SENT>
<SENT sid="1" pm="."><plain>Using cDNA microarray analysis, we found that the epidermal growth factor receptor (EGFR) is expressed in <z:chebi fb="17" ids="38848">FDC</z:chebi> <z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We immunohistochemically examined the expression of EGFR in a larger series of <z:chebi fb="17" ids="38848">FDC</z:chebi> <z:hpo ids='HP_0100242'>sarcomas</z:hpo> and in nonneoplastic <z:chebi fb="17" ids="38848">FDCs</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>This included 8 cases of <z:chebi fb="17" ids="38848">FDC</z:chebi> <z:hpo ids='HP_0100242'>sarcoma</z:hpo>, 12 cases of hyaline vascular <z:e sem="disease" ids="C0017531" disease_type="Disease or Syndrome" abbrv="GLNH|AFLH">Castleman's disease</z:e> (CD), 5 cases of human herpesvirus 8 (HHV8)-positive plasma cell CD, 7 cases of HHV8-negative plasma cell CD, 13 cases of reactive lymph nodes, 3 cases of reactive tonsils, 10 cases of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 6 cases of nodular mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 6 cases of angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>EGFR was expressed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in 7 of 8 cases (88%) of <z:chebi fb="17" ids="38848">FDC</z:chebi> <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (strongly in 4 cases and moderately in 3 cases) </plain></SENT>
<SENT sid="5" pm="."><plain>The single EGFR-negative case had an anaplastic appearance and a more aggressive clinical behavior </plain></SENT>
<SENT sid="6" pm="."><plain>EGFR was also expressed by <z:chebi fb="17" ids="38848">FDC</z:chebi> in <z:hpo ids='HP_0000001'>all</z:hpo> types of CD (strongly in 4 cases, moderately in 16 cases, and weakly in 4 cases) </plain></SENT>
<SENT sid="7" pm="."><plain>Immunostaining results were negative or only weakly positive for EGFR in <z:chebi fb="17" ids="38848">FDC</z:chebi> of reactive lymph nodes and tonsils, and in the <z:chebi fb="17" ids="38848">FDC</z:chebi> networks of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and angioimmunoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The up-regulation of EGFR in <z:chebi fb="17" ids="38848">FDC</z:chebi> of CD was paralleled by an increase in EGFR expression in the surrounding perifollicular fibroblastic reticulum cells suggesting coordinate regulation </plain></SENT>
<SENT sid="9" pm="."><plain>These findings identify a differentially expressed growth regulatory receptor common to both <z:chebi fb="17" ids="38848">FDC</z:chebi> <z:hpo ids='HP_0100242'>sarcoma</z:hpo> and CD, identifying a target for possible therapy in unresectable or refractory cases </plain></SENT>
</text></document>